FDA Approves Titan’s Opioid Dependency Combination Therapy

The FDA has approved Titan Pharmaceuticals’ combination therapy Probuphine for the treatment of opioid dependence.

A buprenorphine implant, Probuphine is designed to provide a constant, low dose of the drug for six months in patients who already take low-to-moderate doses of buprenorphine.

In a clinical study, 63 percent of patients treated with Probuphine had no evidence of illicit opioid use throughout the six months of treatment. Buprenorphine was previously approved only as a pill or a film placed under the tongue or inside of the cheek.